Psychiatrist in professional attire presenting clinical expertise

Roger S. McIntyre, MD, FRCPC

Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (correspondence: [email protected]; 77 Bloor St. W Ste 617, Toronto, Ontario M5S1M2, Canada)

  • 88Articles
  • 536.8KReads1
  • 2001–2026Active
  • 224Collaborators
  • 2.3KCitations2

About

Roger S. McIntyre is affiliated with the Department of Psychiatry and the Department of Pharmacology and Toxicology at the University of Toronto. With a publication record spanning from 2001 to 2026, McIntyre has contributed extensively to clinical topics including major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorders, child and adolescent psychiatry, patient care, weight management, cognition, and neurology. His work explores pharmacodynamic effects following antidepressant cessation, the role of GLP-1 receptor agonists in psychiatric treatment, metabolic dysfunction screening in severe mental disorders, and innovations in precision psychiatry. McIntyre frequently collaborates with authors such as Michael E. Thase and Christoph U. Correll.

Publications

JCP
Distinguishing Bipolar Disorder From MDD: Points to Remember
Insights

Distinguishing Bipolar Disorder From MDD: Points to Remember

April 13, 2021

Dr Roger S. McIntyre highlights 3 important considerations in the differential diagnosis of bipolar disorder and major depressive disorder: age at onset, episode recurrence, and delayed emergence of mania
JCP
Original Research

Predicting Suicidality in Depressive Patients

February 23, 2021

Even given known risk factors for suicide, predicting suicide is difficult. This study used deep learning of structural magnetic resonance imaging to create an algorithm for detecting suicidal ideation...
, , , et al
PCC
Original Research

Efficacy of Cariprazine in Bipolar Disorder

September 17, 2020

Bipolar disorder is characterized by a chronic and subtle course of fluctuating symptoms. To explore the efficacy of cariprazine across the symptoms of bipolar depression, post hoc analyses of...
, , , et al
JCP
Correction

Correction: Oral Ketamine for Depression

April 22, 2020

, , , et al
JCP
Letter to the Editor

Drs Rosenblat and McIntyre Reply

January 28, 2020

 Rosenblat and McIntyre reply to the letter "Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?" by Swainson and Khullar.
,
JCP
Consensus Statement

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
, , , et al
JCP
The Differential Diagnosis of MDD Versus BP
Academic Highlights

The Differential Diagnosis of MDD Versus BP

May 14, 2019

Given the similarity in clinical presentation between major depressive disorder (MDD) and the depressive episodes of bipolar disorder (BP), misdiagnoses occur too often. Read this Academic Highlights to learn...
, , , et al
JCP
Original Research

Psoriasis and Risk of Dementia

May 14, 2019

Find out in this population-based NHIRD study which treatments used for psoriasis can also stave off dementia, another inflammatory disease, and whether the type of dementia is a key...
, , , et al
JCP
Review Article

Oral Ketamine for Depression

April 16, 2019

Intravenous ketamine has rapid and robust antidepressant effects. Read this systematic review to learn if oral ketamine also has efficacy and tolerability in depressed individuals.
, , , et al
JCP
Educational Activity

Addressing Residual Symptoms in Depression

February 20, 2019

Despite the availability of effective treatments for MDD, many individuals have difficulty achieving remission. Residual symptoms can be difficult to differentiate from treatment side effects. Through 2 comic-based case...
PCC
Article

Factors that Impact Treatment Decisions

November 1, 2018

What patient-reported factors influence medication treatment decisions among individuals with bipolar and unipolar depression? The authors of this article conducted a survey to answer this question. Their findings may...
, , , et al
JCP
Review Article

Psychoeducation in the Management of Bipolar Disorder

May 1, 2018

A variety of pharmacologic agents are available for treating your patients with bipolar disorder, but have you considered adding psychoeducation to your armamentarium? This review summarizes the evidence on...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe